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Summary Forty patients with metastatic adenocarcinoma of the prostate were evaluated for response to
treatment with aminoglutethimide plus cortisone acetate. All had relapsed from or failed to respond to
primary endocrine treatment with orchidectomy or stilboestrol. Nineteen patients (48%) showed subjective
response, in most cases relief of bone pain. Side effects limited treatment in only 3 patients. We conclude that
aminoglutethimide plus cortisone acetate is a useful addition to the treatment available for this difficult group
of patients. The mechanism by which this treatment has a beneficial effect remains unclear.
Eighty-five per cent of patients with advanced
adenocarcinoma of the prostate respond to
treatment by orchidectomy or stilboestrol, but all
eventually relapse, most of them with disabling pain
from bony metastases. Treatment of these patients,
many of them elderly and in poor general
condition, is a difficult problem (Lancet, 1980). The
response of some patients to cortisone alone (Miller
& Hinman, 1954) or to bilateral adrenalectomy
(Mahoney & Harrison, 1972; Hendry, 1974)
suggests that in some cases the tumour may retain
sensitivity to residual adrenal androgens.
Aminoglutethimide is an inhibitor of several
enzymes involved in adrenal steroid synthesis
(Dexter et al., 1967) and in prostaglandin
metabolism (Harris et al., 1983c). The combination
of aminoglutethimide and hydrocortisone had
previously been reported both to reduce circulating
levels of adrenal androgen and, in small numbers of
patients, to induce responses in hormone-relapsed
advanced prostatic cancer (Robinson et al., 1974;
Sanford et al., 1976).
The primary clinical goal in these patients is
relief of symptoms rather than objective evidence of
shrinkage of tumour masses. We therefore
evaluated subjective response to aminoglutethimide
plus cortisone acetate in terms of pain, analgesic
requirement, performance status, and the side
effects of treatment in a series of 40 patients. We
also measured circulating adrenal androgens before
and during treatment to examine the relationship
between suppression of androgen levels and clinical
response.
Patients and methods
Patients
This was a multi-centre study. The criteria for
inclusion of patients were: (1) histologically proven
adenocarcinoma of the prostate with relapse from
or failure to respond to primary endocrine therapy
by orchidectomy or stilboestrol, (2) clinical or
radiological evidence of progressive metastatic
disease, and (3) life expectancy >6 weeks.
Exclusions were concurrent endocrine therapy other
than stilboestrol, a history of depression requiring
treatment, judged inability to follow the treatment
regime as an out-patient, previous or concurrent
malignancy at another site, and diabetes mellitus
requiring treatment. To avoid delay in starting
treatment, patients who were on stilboestrol at the
time of referral for the study remained on the same
dose while on aminoglutethimide. If stilboestrol had
been discontinued, at least 4 weeks was allowed to
elapse before starting aminoglutethimide.
Fifty-seven patients were entered; 40 were
evaluable (Table I). The majority (35/40) of
evaluable patients were <75 years of age, and
33/40 were of ECOG performance status 1 or 2
(Table II). 18 patients had previously had
orchidectomy, and 30 had been treated with
stilboestrol (8 in addition to orchidectomy). Of 40
patients, 15 continued on stilboestrol during
treatment with aminoglutethimide. All 40 patients
were evaluable for subjective response; 4 patients
only had measurable soft tissue disease which could
be assessed for objective response.
Treatment
Treatment was aminoglutethimide 250 mg tablets
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Table I Patients entered.
Entered 57
Evaluable 40
Inevaluable 17
died within 4 weeks 7a
protocol violation 7
lost to follow-up 3
aThe primary objective was to evaluate
subjective benefit rather than tumour
regression. The criteria for response
stipulated that it should be maintained for
at least 4 weeks. These 7 patients were
considered inevaluable because even if they
had obtained subjective benefit, they could
not meet these criteria. (Of 3 who were
evaluated 2-3 weeks after starting treatment,
2 did in fact have an improved subjective
score).
twice daily, increased after 2 weeks to 250mg 3
times daily, and after a further 2 weeks to 4 times
daily. Cortisone acetate 25mg twice daily was given
throughout. The dose of aminoglutethimide was
not increased if there were troublesome side effects
(lethargy, depression) nor if the serum creatinine
was greater than 1504umol1-1, because of the
possibility of impaired excretion of
aminoglutethimide in patients with poor renal
function.
Table II Age and performance status at entry
(evaluable patients).
Performance
status
(ECOGscale) 55-59 60-64 65-69 70-74 75-79 80-84 Total
0 2 - 2
1 3 2 5 4 - 2 16
2 3 4 2 4 2 - 15
3 1 2 3 1 7
4
Total 6 9 9 11 2 3 40
Assessment ofsubjective response
The scoring system for subjective response is shown
in Table III. Response was defined as an
improvement in the total score by 2 points or more,
sustained over consecutive occasions at least 4
weeks apart. Patients were stabilised on an
analgesic regime and, wherever possible, discharged
from hospital before commencing
aminoglutethimide so as to provide a proper
baseline. The assessment was repeated at 2 weeks
and 4 weeks after starting treatment, and every 4
weeks thereafter.
Other criteria ofresponse and side effects
Bloods were taken at each visit for Hb, WBC,
Table III Scoring system for subjective response.
Performance status (ECOG)
Fully active
Active, capable oflight work/domestic tasks
Restricted; in bed <50% of time; capable of self-care
Restricted; in bed >50% oftime; limited self-care
Bedridden
Analgesic requirement
None, or no requirement for analgesics
Non-narcotic analgesics - occasional
- regular
Oral or parenteral narcotic analgesics - occasional
- regular
Assessment ofpain
None
Slight/mild; little interference with non-strenuous activities
Quite bad; interferes with daily activites and/or sleep
Severe; distracted by pain for much of the time
Intolerable; dominates existence
0
2
3
4
0
1°
2
3
4
0
1
2
3
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platelets, bilirubin, creatinine, acid and alkaline
phosphatases. Bone scans and X rays of positive
areas were taken before treatment and at intervals
of 3 months. Evaluable tumour was recorded at
each visit. Side effects were sought first by open
and then by specific enquiries. Urine glucose and
lying and standing blood pressure were recorded at
each visit.
Hormone studies
Ten ml of serum was taken before treatment and at
each visit, separated and stored at -20°C.
Hormone assays were carried out in 2 batches at
the end of the study. Dehydroepiandrosterone
sulphate (DHA-S) (Harris et al., 1982), A4 andro-
stenedione (Dowsett et al., 1984) and sex hormone
binding globulin (SHBG) (Iqbal & Johnson, 1977)
were measured according to previously described
methodology. Testosterone was measured using the
EIR-RIA kit which employs a 1251-testosterone
tracer and has a sensitivity of 0.10nmol -1. Within
and between assay coefficients of variation (CV)
were 5.8% and 9.3% respectively at a serum
concentration of 2nmol 1-l. 5a-dihydrotesterone
(SaDHT) was measured by radioimmunoassay after
oxidation of testosterone to a glycol of insignificant
cross-reactivity. The sensitivity of the assay was
0.10nmol1-1 and the within and between assay
CVs were 6.2% and 11.1% respectively at a serum
concentration of 0.7nmolI1.
Results
Nineteen out of 40 patients obtained a subjective
response. The magnitude of the response is shown
in Table IV. Of 33 patients in whom bone pain was
the dominant symptom, 17 (51%) obtained benefit
by the same criteria: an improvement of pain
assessment score by at least 2 points, lasting for at
least 4 weeks. None of the 4 patients with
measurable soft-tissue disease responded by a
sustained reduction of more than 50% in the area
of the lesions.
Table IV Peak improvement in
subjective response score maintained
for at least 4 weeks in 19 responders.
Improvement in score
2-3
4-5
6-7
8-9
10-12
Seventeen of the 19 responses were apparent
within 2 weeks of starting treatment. The median
duration of response was 8 months, with 5/19
responders sustaining response for more than 1
year (Figure 1). After relapse from amino-
glutethimide, the acturial median survival of the 14
responders who have so far relapsed is 6 months.
The probability of response was not clearly
predicted by previous response to endocrine
treatment, by length of history before starting
aminoglutethimide, by age, performance status, or
subjective score at starting treatment, but the
numbers are so small that only major effects would
be apparent. The relationship between subjective
response, responses in terms of bone scan and
phosphatases and the response categories defined
by the US National Prostate Cancer Project
(NPCP) (Schmidt et al., 1980) is shown in Table V.
One of the 2 patients having a CR in terms of acid
phosphatase was judged to have new osteoblastic
lesions on X-ray, and so did not qualify as a
responder by NPCP criteria.
Side effects
In general, treatment was well tolerated and easy to
give. The commonest side effects were mild lethargy
and depression (Table VI), which generally
occurred within the first week and subsided within
a few days without the need to interrupt treatment.
In 3 patients, lethargy was severe; in 2 of these,
treatment had to be abandoned. The other severe
side-effect was an episode ofcollapse in one patient
which was suspected (but not proven) to be hypo-
adrenal in origin. It could not be established
whether he had taken his cortisone acetate reliably.
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Figure 1 Duration of subjective response to
aminoglutethimide.
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Table V Subjective response vs bone scan and phosphatases and vs US National Prostate
Cancer Project criteria for response.
Acid US NPCP criteria
Alkaline phosphatase for objective
Scan phosphatase (tartate labile) response
Subjective
Responders
(19)
CR 0
(10)
PR 3
CR 1
(14)
PR 1
CR 2 CR
(14) PR
PR 4 Stable
Non-responders
(21)
CR 0 CR 0
(6) (9)
PR 1 PR 0
CR 0 CR
(9) PR
PR 2 Stable
Criteria:
bone scan: CR=disappearance of all lesions.
PR =reduction in number of lesions and intensity.
phosphatases: inevaluable unless initial value at least 3 x upper limit of normal.
CR= return to normal.
PR=at least 50% reduction; both sustained for at least 2 measurements 4
weeks apart.
Figure in brackets denotes number evaluable. United States National Prostate Cancer Project criteria are listed in Schmidt et al. (1980).
Table VI Side-effects of Aminoglutethimide treatment.
None Mild Moderate Severe
Lethargy 6 22 9 3 40
Depression 21 12 7 - 40
Skin rash 34 4 2 40
Other 35 4 1 40
Postural hypotension was not reported in other
patients on treatment. Six patients had the transient
skin rash previously associated with amino-
glutethimide (Murray et al., 1981). Other notable
side effects included Warfarin resistance in one
patient on anti-coagulant therapy, and transient
thrombocytopenia (9 x 104Mmm-3) associated with
skin rash, which resolved despite continued amino-
glutethimide treatment. Both these have been noted
before (Murray et al., 1981).
There was no correlation between the incidence
of side-effects and levels of serum creatinine or
bilirubin.
Hormone studies
Fourteen patients (6 subjective responders and 8
non-responders) had adequate samples for
evaluation of A4 androstenedione, DHA-S and
testosterone, and 10 patients (5 responders and 5
non-responders) for 5aDHT. Eight of the 14
patients had previously had orchidectomy; 1 of
these had subsequently been treated with
stilboestrol mgt.d.s. and remained on this dose.
The remaining 6 patients were also all taking
stilboestrol mgt.d.s.
The patients on stilboestrol had raised SHBG,
but without any evident difference in androgen
levels compared with those not on stilboestrol. Pre-
and on-treatment values of androgens are shown in
Figure 2. There are significant decreases in the
levels of testosterone, A4 androstenedione and
DHA-S (P=0.01, P=0.05, P=0.02 respectively,
Wilcoxon Matched Pairs Test), and a drop, though
not significant (P=0.16), in the levels of 5axDHT.
For none of the four hormones is the change in
hormone levels in subjective responders and non-
responders significantly different (P=0.50, 0.23,
0.25, 0.21) - however, these comparisons have very low power.
Discussion
Responses to aminoglutethimide in combination
with corticosteroid in advanced prostatic cancer
were originally reported in small series of patients by Robinson et al. (1974) and by Sanford et al.
(1976). More recently Rostom et al. (1982) have
reported subjective benefit in 9/12 patients, and
Worgul et al. (1983) and Drago et al. (1984) have
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Figure 2 Hormone levels immediately before starting treatment and 1-3 months after.
pre=immediately before treatment.
post= average of all samples between 1 and 3 months.
R =responders.
NR =non-responders.
dotted line=detection limit of assay.
* =3 patients classified as having objectively stable disease by NPCP criteria (see Table V).
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reported complete or partial objective responses by
the American National Prostate Cancer Group
criteria in 7 of 43 patients. Block et al. (1983),
however, found no evidence of objective response in
19 patients. In each series, treatment was associated
with a decrease in circulating androgens, and in the
series of Rostom et al. (1982) there was a
suggestion that this was correlated with response.
Our results in 40 patients confirm that amino-
glutethimide in combination with a corticosteroid
offers useful subjective benefit in approximately
half of those patients with symptomatic hormone-
relapsed prostate cancer. Responses are obtained
quickly, and are occasionally associated with
dramatic improvement in the ability of the patient
to lead an active life. The treatment is in general
well tolerated and practicable for elderly patients
living at home. The dose regime which we used was
designed to minimise the side effects which are
most commonly seen within the first week of
treatment. Both the onset of subjective response
and the timing of the endocrine changes (not
shown) indicate that the major effects of treatment
were already apparent within the first two weeks;
that is, on the lowest dose of 250mg amino-
glutethimide twice daily. This result must be inter-
preted with caution, both because aminoglutethi-
mide has been reported to induce its own metabol-
ism (Murray et al., 1979), and because the role of
aminoglutethimide in producing the clinical
response is still unclear (see below). Nevertheless, as
in the treatment of breast cancer (Harris et al.,
1983a, 1983b) it suggests that the lower dose of
aminoglutethimide may be sufficient for therapeutic
effect, and higher doses may merely increase the
incidence of side effects.
Although the regime of aminoglutethimide plus
corticosteroid is effective, it is not clear how it
works. Inhibition of adrenal androgen production
provided the original rationale, in view of the
responses obtained by surgical adrenalectomy
(Mahoney & Harrison, 1972; Hendry, 1974).
Worgul et al. (1983) nevertheless questioned
whether the decreases in androgen levels with
treatment in their patients were necessarily of
biological significance, and the same question is
posed by our finding that the measured effects on
androgen levels were no different between
responders and non-responders. This might be
explained by different androgen sensitivity of
responsive and non-responsive tumours.
Alternatively, the effects of aminoglutethimide
might be due to inhibition of oestrogen production
by inhibition of the aromatase enzyme (Harris et
al., 1983b; Santen et al., 1978). There is evidence
from experimental animals that oestrogens may be
important for the maintenance of androgen
receptors in prostatic tissue (Moore et al., 1979).
Another possibility is that the effects might be
independent of adrenal action, and the result of the
inhibition by aminoglutethimide of the cytochrome
P-450 dependent cyclo oxygenase which is involved
in arachidonic acid metabolism and prostaglandin
synthesis (Harris et al., 1983c). That several
patients who obtained relief were already taking
analgesics which are inhibitors of prostaglandin
synthesis perhaps argues against this. Finally, the
possibility must be considered that all of the
subjective responses were due to the cortisone
acetate alone, either adrenal suppression (Miller &
Hinman, 1954) or anti-prostaglandin effects (Harris
et al., 1983c), and not due to aminoglutethimide at
all. No data at present exist about the hormonal
effects of cortisone alone versus aminoglutethimide
plus cortisone in orchidectomised men. We are now
addressing this question and the relative
contribution of cortisone and aminoglutethimide to
the clinical response. In this context it may be
noted that aminoglutethimide alone would be
predicted to cause a rise in androstenedione and
possibly testosterone levels, which might not be of
benefit to the patients.
The alternatives to aminoglutethimide plus
cortisone in the treatment of advanced prostatic
cancer include other hormonal agents, for example
the anti-oestrogen tamoxifen (Glick et al., 1982)
and the anti-androgen cyproterone acetate,
chemotherapy (Schmidt, 1980; Citrin et al., 1983),
hemibody irradiation (Epstein et al., 1979), and
pituitary ablation (Fitzpatrick et al., 1980;
Fergusson & Hendry, 1971; Tindall et al., 1979).
Similar broad ranges of response have been
reported for each; the data do not exist which will
allow a formal comparison. The endocrinology of
prostate cancer is not yet sufficiently well
understood to allow the selection of patients for
hormone treatment or the rational design of new
endocrine regimes. The choice of treatment is
therefore empirical. Aminoglutethimide plus
cortisone is a valuable addition to the treatments
which are available.
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